Peptidoglycan complex of spirulina (Beijing Huashitianfu Biopharmaceutical)

N/A

Report date: 2024/11/28 14:33:17

Base Information

Drug NamePeptidoglycan complex of spirulina (Beijing Huashitianfu Biopharmaceutical)
Drug Alias NamePeptidoglycan complex of spirulinaK-001
ClassificationBiologicsNatural product/Extract > Microbial extract
Mechanisms of ActionPeroxisome proliferator-activated receptor α agonistsSodium/glucose cotransporter 2 inhibitors
TargetsPeroxisome proliferator-activated receptor αSodium/glucose cotransporter 2
Therapy Area/IndicationsPancreatic NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesHwealth PharmaceuticalShanghai Jiao Tong University School of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesHwealth PharmaceuticalKowa Research Institute Inc
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A